Following the procedure described for the preparation of N-((1S)-1-{[((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)amino]carbonyl}-3-methylbutyl)-4-methoxy-1H-indole-2-carboxamide but substituting N2-(tert-butoxycarbonyl)-N1-((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)-4-methyl-l-leucinamide and (2R)-tetrahydrofuran-2-carboxylic acid and making noncritical variations provided a crude product. This crude material was purified by Biotage MPLC (40 M cartridge, chloroform mobile phase with 2% methanol followed by 3% methanol, sample loaded in chloroform) resulting in the isolation of 1.13 g (61%) of the title compound as a light yellow foam. Rf = 0.27 (95:5 dichloromethane/methanol); 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J = 8 Hz, 1H), 7.72 (d, J = 8 Hz, 1H), 7.68 (s, 1H), 4.55 (s, 2H), 4.44–4.36 (m, 1H), 4.35–4.27 (m, 1H), 4.21 (dd, J = 8, 5 Hz, 1H), 3.95–3.86 (m, 1H), 3.79–3.71 (m, 1H), 3.18–3.07 (m, 2H), 2.21 (td, J = 9, 4 Hz, 1H), 2.13–2.03 (m, 2H), 1.97–1.88 (m, 1H), 1.85–1.74 (m, 3H), 1.68–1.56 (m, 4H), 0.88 (s, 9H); MS (ESI+) for C20H32ClN3O5m/z 430 (M + H).